Significant gene induction was also observed with synthetic GPR40 agonists proposed to have clinical potential for type-2 diabetes mellitus and hepatic steatosis, i.e. GW9508 (40), TAK-875 (fasiglifam) (41), and the anti-diabetic drug rosiglitazone (AvandiaTM) from the thiazolidinedione family (42) (Figure 1D). This evidence concerns the gene FFAR1 and fatty liver disease.